EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α ‐ positive ovarian cancer: Justification of therapeutic dose regimen

Ya-Ping Tu iD, H Maxime Lagraauw iD, Michael Method, Yuemei Wang, Eva Hanze, Lingling Li, Timothy Parrott, Callum M Sloss, Eric H Westin

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16250 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Ya-Ping Tu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, ImmunoGen, Waltham, MA, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Folate Receptor 1, Maytansine, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to investigate exposure–response (ER) relationships in efficacy and safety for mirvetuximab soravtansine (MIRV) which is a first‐in‐class antibody–drug conjugate approved for the treatment of folate receptor‐α‐positive platinum‐resistant ovarian cancer.

Methods

MIRV was characterized in 4 clinical studies. Exposure metrics for MIRV, its payload and a metabolite were derived from a population pharmacokinetic model. Efficacy was analysed in MIRV‐treated patients ( n = 215) in a recent confirmatory, randomized, chemotherapy‐controlled MIRASOL trial and safety was evaluated in patients pooled across all 4 clinical studies ( n = 757).

Results

In the MIRASOL trial (NCT04209855), MIRV demonstrated significant benefit over chemotherapy in progression‐free survival (PFS), objective response rate (ORR) and overall survival (OS). The most common adverse events (AEs) included ocular disorders, peripheral neuropathy and pneumonitis. For PFS, ORR and OS, the trough concentration of MIRV was the predictor consistently found in ER models for efficacy. In contrast, for ocular AEs (as well as the time to onset of ocular AEs) and peripheral neuropathy, the area under the concentration–time curve (AUC) of MIRV was identified as the exposure metric in ER models for safety. No exposure parameters were found to correlate with pneumonitis. Covariates in all models did not show clinically meaningful impact on efficacy or safety. Logistic regression models for ORR and ocular AEs based on AUC of MIRV were used to justify the clinical dose regimen approved for MIRV.

Conclusion

The trough concentration of MIRV correlated with efficacy whereas the AUC of MIRV was associated with major AEs. The ER relationships supported the selected therapeutic dose regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsFolate Receptor 1MaytansineAntibodies, Monoclonal, HumanizedImmunoconjugatesDose-Response Relationship, DrugHumansFemaleMiddle AgedAgedAdultProgression-Free SurvivalAged, 80 and overModels, Biological

Stichwörter der Autor:innen

antibody–drug conjugateexposure–response relationshipfolate receptormirvetuximab soravtansine, ovarian cancer

Substanzen

mirvetuximab soravtansineFolate Receptor 1MaytansineAntibodies, Monoclonal, HumanizedImmunoconjugatesFOLR1 protein, human

Autor:innen und Institutionen

  • Clinical Pharmacology, ImmunoGen, Waltham, MA, USA.
  • qPharmetra LLC, Nijmegen, The Netherlands.
  • Clinical Development, ImmunoGen, Waltham, MA, USA.
  • Biostatistics, ImmunoGen, Waltham, MA, USA.
  • Pharmacovigilance, ImmunoGen, Waltham, MA, USA.
  • Translational Science, ImmunoGen, Waltham, MA, USA.

ORCID-Profile: Ya-Ping Tu, H Maxime Lagraauw

Zitieren

APA

Tu, Y. P., Lagraauw, H. M., Method, M., Wang, Y., Hanze, E., Li, L., Parrott, T., Sloss, C. M., & Westin, E. H. (2025). Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α ‐ positive ovarian cancer: Justification of therapeutic dose regimen. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16250

Vancouver

Tu YP, Lagraauw HM, Method M, Wang Y, Hanze E, Li L, et al. Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α ‐ positive ovarian cancer: Justification of therapeutic dose regimen. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16250

BibTeX
@article{Tu2025,
  author = {Tu, Ya-Ping and Lagraauw, H Maxime and Method, Michael and Wang, Yuemei and Hanze, Eva and Li, Lingling and Parrott, Timothy and Sloss, Callum M and Westin, Eric H},
  title = {Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α ‐ positive ovarian cancer: Justification of therapeutic dose regimen},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16250}
}
Kostenlos starten →